HeartSciences Inc. reported the passing of Mark Hilz, the Chief Operating Officer and Corporate Secretary, on April 1, 2026, at the age of 67 following a period of illness. Hilz had been with the company since 2013 and served as COO since March 2022. The company expressed its condolences to his family and friends, highlighting his contributions as a visionary leader. Despite this significant loss, HeartSciences does not anticipate any immediate changes to its leadership structure or operational strategy. The company has recently launched its MyoVista Insights software platform and submitted its MyoVista wavECG device for FDA clearance, indicating that it will continue its planned commercialization efforts without interruption. This stability in leadership and ongoing projects may mitigate potential negative impacts on the company's stock performance, although the loss of a key executive is generally viewed as a negative event in the corporate governance landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.